Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics

Abstract INTRODUCTION With the advent of disease‐modifying therapies, accurate assessment of biomarkers indicating the presence of disease‐associated amyloid beta (Aβ) pathology becomes crucial in patients with clinically suspected Alzheimer's disease (AD). We evaluated Aβ levels in cerebrospinal fl...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Matthias Brendel, Tandis Parvizi, Johannes Gnörich, Christof Elias Topfstedt, Katharina Buerger, Daniel Janowitz, Boris‐Stephan Rauchmann, Robert Perneczky, Carolin Kurz, Dirk Mehrens, Wolfgang G. Kunz, Julia Kusche‐Palenga, Agnes Bernadette Kling, Antonia Buchal, Elizabet Nestorova, Sara Silvaieh, Raphael Wurm, Tatjana Traub‐Weidinger, Sigrid Klotz, Günther Regelsberger, Axel Rominger, Alexander Drzezga, Johannes Levin, Elisabeth Stögmann, Nicolai Franzmeier, Günter U. Höglinger
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-10-01
Rangatū:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Ngā marau:	Alzheimer's disease biomarkers cerebrospinal fluid dementia positron emission tomography real world
Urunga tuihono:	https://doi.org/10.1002/dad2.70031
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!